BioSpace News Archive

PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.

Emergency funding to support immediate action to prevent the spread of the new coronavirus

BayCare Health System on Friday announced refinements to its drive-thru COVID-19 testing sites to ensure that patients who are most at risk are the ones being tested.

Leading health tech company is the first to introduce novel approach to addressing the COVID-19 pandemic

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency expanded access allowing its proprietary inhaled nitric oxide (iNO) delivery system, INOpulse®, to immediately be used for the treatment of COVID-19. NO is a naturally produced molecule that is critical to the immune response against path

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces support for global COVID-19 research efforts via a new Coronavirus Toolkit featuring relevant models and services. Mouse models have been extensively used for research on the SARS-CoV virus, closely related to the new SARS-CoV-2 virus that causes COVID-19. Taconic offers many animal models and services to support COVID-19 research and em

March 20, 2020 12:30 UTC Series A Financing Funds Novel Pipeline for Patients with Nucleotide Repeat Disorders Company Advancing Lead Program for Friedreich’s Ataxia toward Clinical Development SAN DIEGO--( BUSINESS WIRE )-- Design Therapeutics announced today that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions. The company has closed a $45 million Series A fina

Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also granted by Health Canada CABENUVA reduces treatment dosing days from 365 to 12 per year

German companies CureVac and BioNTech were both in the headlines this week as companies working overtime to develop a vaccine to prevent the spread of coronavirus.

Directive mandates reimbursement coverage of Tumor Treating Fields for patients with newly diagnosed glioblastoma by the compulsory health insurance system